Related references
Note: Only part of the references are listed.Avapritinib in advanced gastrointestinal stromal tumor: case series and review of the literature from a tertiary care center in India
Saurav Verma et al.
FUTURE SCIENCE OA (2021)
Imatinib, sunitinib and pazopanib: From flat-fixed dosing towards a pharmacokinetically guided personalized dose
Kim Westerdijk et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2020)
Discovery and pharmacological characterization of AZD3229, a potent KIT/PDGFRα inhibitor for treatment of gastrointestinal stromal tumors
Erica Banks et al.
SCIENCE TRANSLATIONAL MEDICINE (2020)
Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial
Jean-Yves Blay et al.
LANCET ONCOLOGY (2020)
Hepatic toxicity during regorafenib treatment in patients with metastatic gastrointestinal stromal tumors
Philipp Ivanyi et al.
MOLECULAR AND CLINICAL ONCOLOGY (2020)
A phase Ib study of BGJ398, a pan-FGFR kinase inhibitor in combination with imatinib in patients with advanced gastrointestinal stromal tumor
Ciara M. Kelly et al.
INVESTIGATIONAL NEW DRUGS (2019)
Secondary KIT mutations: the GIST of drug resistance and sensitivity
Andrea Napolitano et al.
BRITISH JOURNAL OF CANCER (2019)
Discovery of (E)-N1-(3-Fluorophenyl)-N3-(3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)malonamide (CHMFL-KIT-033) as a Novel c-KIT T670I Mutant Selective Kinase Inhibitor for Gastrointestinal Stromal Tumors (GISTs)
Xuesong Liu et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
Preclinical development of HQP1351, a multikinase inhibitor targeting a broad spectrum of mutant KIT kinases, for the treatment of imatinib-resistant gastrointestinal stromal tumors
Xuechao Liu et al.
CELL AND BIOSCIENCE (2019)
Fibroblast growth factor receptors as treatment targets in clinical oncology
Masaru Katoh
NATURE REVIEWS CLINICAL ONCOLOGY (2019)
Ponatinib: a novel multi-tyrosine kinase inhibitor against human malignancies
Fiona H. Tan et al.
ONCOTARGETS AND THERAPY (2019)
Axitinib overcomes multiple imatinib resistant cKIT mutations including the gatekeeper mutation T670I in gastrointestinal stromal tumors
Feiyang Liu et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2019)
Discovery of (S)-2-amino-N-(5-(6-chloro-5-(3-methylphenylsulfonamido)pyridin-3-yl)-4-methylthiazol-2-yl)-3-methylbutanamide (CHMFL-PI3KD-317) as a potent and selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor
Xiaofei Liang et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2018)
Anlotinib inhibits angiogenesis &ITvia&IT suppressing the activation of VEGFR2, PDGFRβ and FGFR1
Binyan Lin et al.
GENE (2018)
Current clinical management of gastrointestinal stromal tumor
Kazuya Akahoshi et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2018)
Preclinical Evaluation of Nintedanib, a Triple Angiokinase Inhibitor, in Soft-tissue Sarcoma: Potential Therapeutic Implication for Synovial Sarcoma
Parag P. Patwardhan et al.
MOLECULAR CANCER THERAPEUTICS (2018)
Double strand break repair and γ-H2AX formation in erythrocytes of medaka (Oryzias latipes) after γ-irradiation
Alaa El-Din Hamid Sayed et al.
ENVIRONMENTAL POLLUTION (2017)
Genomic and Transcriptomic Tnalysis of Imatinib Resistance in Gastrointestinal Stromal Tumors
Tsuyoshi Takahashi et al.
GENES CHROMOSOMES & CANCER (2017)
Discovery of a highly selective KIT kinase primary V559D mutant inhibitor for gastrointestinal stromal tumors (GISTs)
Kailin Yu et al.
ONCOTARGET (2017)
Dovitinib in patients with gastrointestinal stromal tumour refractory and/or intolerant to imatinib
Heikki Joensuu et al.
BRITISH JOURNAL OF CANCER (2017)
Gastrointestinal stromal tumors (GISTs): point mutations matter in management, a review
Peter J. Oppelt et al.
JOURNAL OF GASTROINTESTINAL ONCOLOGY (2017)
Global epidemiology of gastrointestinal stromal tumours (GIST): A systematic review of population-based cohort studies
Kjetil Soreide et al.
CANCER EPIDEMIOLOGY (2016)
Discovery of N-((1-(4-(3-(3-((6,7-Dimethoxyquinolin-3-yl)oxy)phenyl)ureido)-2-(trifluoromethyl)phenyl)piperidin-4-yl)methyl)propionamide (CHMFL-KIT-8140) as a Highly Potent Type II Inhibitor Capable of Inhibiting the T670I Gatekeeper Mutant of cKIT Kinase
Binhua Li et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
Pazopanib plus best supportive care versus best supportive care alone in advanced gastrointestinal stromal tumours resistant to imatinib and sunitinib (PAZOGIST): a randomised, multicentre, open-label phase 2 trial
Olivier Mir et al.
LANCET ONCOLOGY (2016)
Sunitinib in the treatment of gastrointestinal stromal tumor: patient selection and perspectives
Nuria Mulet-Margalef et al.
ONCOTARGETS AND THERAPY (2016)
Nintedanib: examining the development and mechanism of action of a novel triple angiokinase inhibitor
Martin Reck
EXPERT REVIEW OF ANTICANCER THERAPY (2015)
FGFR-Mediated Reactivation of MAPK Signaling Attenuates Antitumor Effects of Imatinib in Gastrointestinal Stromal Tumors
Fang Li et al.
CANCER DISCOVERY (2015)
Nintedanib in non-small cell lung cancer: from preclinical to approval
Christian Caglevic et al.
THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE (2015)
Crosstalk between KIT and FGFR3 Promotes Gastrointestinal Stromal Tumor Cell Growth and Drug Resistance
Nathalie Javidi-Sharifi et al.
CANCER RESEARCH (2015)
A Multi-parameter In Vitro Screen in Human Stem Cell-Derived Cardiomyocytes Identifies Ponatinib-Induced Structural and Functional Cardiac Toxicity
Dominique R. Talbert et al.
TOXICOLOGICAL SCIENCES (2015)
Ponatinib Inhibits Polyclonal Drug-Resistant KIT Oncoproteins and Shows Therapeutic Potential in Heavily Pretreated Gastrointestinal Stromal Tumor (GIST) Patients
Andrew P. Garner et al.
CLINICAL CANCER RESEARCH (2014)
Regorafenib in gastrointestinal stromal tumors: clinical evidence and place in therapy
Danielle Ferraro et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2014)
Amplification of FRS2 and Activation of FGFR/FRS2 Signaling Pathway in High-Grade Liposarcoma
Keqiang Zhang et al.
CANCER RESEARCH (2013)
A gist of gastrointestinal stromal tumors: A review
Ashwin Rammohan et al.
WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY (2013)
Current and emerging strategies for the management of imatinib-refractory advanced gastrointestinal stromal tumors
Damien Kee et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2012)
Fibroblast growth factors and their receptors in cancer
Jorgen Wesche et al.
BIOCHEMICAL JOURNAL (2011)
Imatinib treatment for gastrointestinal stromal tumour (GIST)
Lisandro F. Lopes et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2010)
Fibroblast growth factor signalling: from development to cancer
Nicholas Turner et al.
NATURE REVIEWS CANCER (2010)
Resistance to Tyrosine Kinase Inhibitors in Gastrointestinal Stromal Tumors
Ann W. Gramza et al.
CLINICAL CANCER RESEARCH (2009)
Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure
S. George et al.
EUROPEAN JOURNAL OF CANCER (2009)
KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients
Ketan S. Gajiwala et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Primary and Secondary Kinase Genotypes Correlate With the Biological and Clinical Activity of Sunitinib in Imatinib-Resistant Gastrointestinal Stromal Tumor
Michael C. Heinrich et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Kit as a human oncogenic tyrosine kinase
Y Kitamura et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2004)
Share Paper
